论文部分内容阅读
医药购销领域商业贿赂问题是近年来社会比较关注的热点话题。2013年7月,英国最大制药公司葛兰素史克涉嫌在华经济贿赂一事开始浮出水面并迅速扩大事态。一时间,包括美国辉瑞、法国赛诺菲、瑞士诺华等多家全球最知名跨国制药公司,纷纷被传出开始接受中国相关政府部门调查的消息。医药生产、经营企业以回扣、提成等方式对医疗机构及其医务人员进行商业贿赂,导致医药服务价格不断攀升,医务人员为获得
The issue of commercial bribery in the field of medicine purchase and sale is a hot topic of social concern in recent years. In July 2013, GlaxoSmithKline, Britain’s largest pharmaceutical company, started to surface the issue of economic bribery in China and rapidly expanded the situation. For a time, many of the world’s most famous multinational pharmaceutical companies, including Pfizer in the United States, Sanofi in France and Novartis in Switzerland, have been rumored to be receiving investigation from relevant Chinese government departments. Pharmaceutical production and business enterprises rebate, commission and other means of medical institutions and their medical staff for commercial bribery, leading to the rising price of medical services, medical staff to obtain